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ABSTRACT
Antimicrobial susceptibilities of 244 amoxycillin-
non-susceptible and 81 amoxycillin-susceptible
pneumococcal isolates from 15 Spanish hospitals
were determined and clonal relationships were
investigated by pulsed-field gel electrophoresis
after SmaI restriction. Amoxycillin-non-suscept-
ible isolates exhibited higher rates of resistance to
cefuroxime, cefixime, cefpodoxime and clarithro-
mycin, but not to levofloxacin and cefotaxime.
Cefditoren exhibited MIC90 values one dilution
lower than those of cefotaxime. Higher numbers
of the Spain14-5 and Spain6B-2 clones, but not the
Spain9V-3 and Spain23F-1 clones, were found
among amoxycillin-non-susceptible isolates.
Spain14-5 was the most problematic clone in terms
of antibiotic resistance.
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It has been suggested that antibiotic consump-
tion, together with the spread of individual
clones, specific recombinational events and ⁄ or
point mutations, is one of the main driving
forces of antibiotic resistance in Streptococcus
pneumoniae. In Spain, erythromycin resistance in
pneumococci remained relatively stable (c. 35%)
between 1996 and 2002, and penicillin resistance
decreased from 37% in 1996–1997 to 20% in
2001–2002 [1]. However, non-susceptibility to
amoxycillin (with or without clavulanate), which
is the antibiotic that is prescribed most frequently
for respiratory tract infections in the community,
remained at c. 9% during 1998–1999 and 2001–
2002, but at c. 40% among penicillin-resistant
isolates [1,2]. The emergence of resistance to
amoxycillin within pre-existing penicillin-resis-
tant clones is now also associated with macrolide
and ciprofloxacin resistance [1,3,4]. The aim of
the present study was to investigate the in-vitro
activity of seven b-lactams, two macrolides and
one fluoroquinolone against amoxycillin-non-
susceptible S. pneumoniae isolates exhibiting
higher amoxycillin MICs than penicillin MICs,
using amoxycillin-susceptible, penicillin-non-
susceptible isolates as controls.
The 325 penicillin-non-susceptible (MIC
‡0.12 mg ⁄L) S. pneumoniae clinical isolates stud-
ied were identified to the species level by colony
morphology, Gram’s stain, optochin susceptibility
and bile solubility tests. The isolates were sero-
typed using the Quellung reaction (Quellung
antisera; Statum Serum Institute, Copenhagen,
Denmark). Overall, 244 isolates were non-
susceptible to amoxycillin (MIC ‡4 mg ⁄L), with
higher amoxycillin MICs than penicillin MICs,
and 81 isolates were amoxycillin-susceptible (MIC
£2 mg ⁄L). Of the 244 amoxycillin-non-susceptible
isolates with a higher amoxycillin MIC than
penicillin MIC, 165 had been characterised previ-
ously [4]. The remaining 79 were non-duplicate
isolates from the S. pneumoniae collection of Hos-
pital Donostia, Gipuzkoa, northern Spain, isolated
during the last decade. Twenty-nine of these 244
isolates were invasive isolates (26 from blood, two
from cerebrospinal fluid, one from pleural
fluid) and 215 were isolated from respiratory
specimens. For comparison purposes, 81 amoxy-
cillin-susceptible (MIC £2 mg ⁄L), penicillin-non-
susceptible (MIC ‡0.12 mg ⁄L) isolates were
selected randomly from the S. pneumoniae collec-
tion of Hospital Donostia, of which 16 were
invasive isolates (14 from blood and two from
cerebrospinal fluid) and 65 were isolated from
respiratory specimens.
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Antimicrobial susceptibilities to penicillin,
amoxycillin–clavulanic acid (2:1), cefuroxime axe-
til, cefixime, cefpodoxime, cefotaxime, cefditoren,
erythromycin, clarithromycin and levofloxacin
were determined by microdilution in Mueller–
Hinton broth supplemented with lysed horse
blood 3–5% v ⁄ v, according to CLSI guidelines
[5], using custom-designed 96-well trays (Sensi-
titre; Trek Diagnostics, Westlake, OH, USA) and a
range of concentrations of each antimicrobial
agent, including at least one dilution higher and
lower than the susceptible and resistant break-
points. Staphylococcus aureus ATCC 29213 and
S. pneumoniae ATCC 49619 were used as control
strains. Susceptibility and resistance breakpoints
(mg ⁄L) were those recommended by the CLSI [5]:
i.e., penicillin £0.06 ⁄ ‡2; amoxycillin–clavulanic
acid £2 ⁄ ‡8; cefuroxime axetil £1 ⁄ ‡4; cefpodoxime
£0.5 ⁄ ‡2; cefotaxime £1 ⁄ ‡4; erythromycin and
clarithromycin £0.25 ⁄ ‡1; and levofloxacin £2 ⁄ ‡8.
There are no CLSI breakpoints defined for cefix-
ime and cefditoren.
To determine clonality, pulsed-field gel
electrophoresis (PFGE) was used to analyse 243
randomly selected isolates (188 amoxycillin-
non-susceptible and 55 amoxycillin-susceptible),
representing 75% of the isolates included in the
study. Genomic DNA was prepared, digested with
SmaI (New England Biolabs, Beverly, MA, USA)
and analysed by PFGE as described previously [6].
PFGE patterns were analysed using the Diversity
Database fingerprinting software v.2 (Bio-Rad
Laboratories, Hercules, CA, USA) and a dendo-
gram was constructed using the unweighted
pair-group method with arithmetic averages, the
Dice coefficient and a position tolerance of 1%.
Four reference isolates of the Spanish multidrug-
resistant clones Spain23F-1 (ATCC 70669), Spain6B-
2 (ATCC 700670), Spain9V-3 (ATCC 700671) and
Spain14-5 (ATCC 700902) were used as controls.
Isolates showing a PFGE pattern homology of
>80%, representing a variation of less than three
bands between two PFGE patterns, were assigned
to the same clone. Statistical comparisons between
amoxycillin-non-susceptible and amoxycillin-
susceptible isolates were determined using the
chi-square test or Fisher’s exact test with Yates’
correction, as appropriate, with p <0.05 considered
to be statistically significant.
Table 1 shows the number and cumulative
percentage of isolates inhibited at different con-
centrations of antimicrobial agents, as well as the
Table 1. Distribution of MICs for Streptococcus pneumoniae isolates, grouped according to their amoxycillin susceptibility,
showing the number of isolates inhibited (cumulative percentage) at different antibiotic concentrations (mg ⁄L)
MIC (mg ⁄L)
0.12 0.25 0.5 1 2 4 8 ‡16 %S %I %R
Amoxycillin-non-susceptible
(MIC ‡4 mg ⁄L)
isolates (n = 244)
PEN 51 (20.9) 162 (87.3) 31 (100) 0 22.1 77.9
AMC 124 (50.8) 117 (98.8) 3 (100) 0 50.8 49.2
CXM 64 (26.2) 138 (82.8) 42 (100) 0 0 100
CFM 2 (0.8) 50 (21.3) 192 (100) NA NA NA
CPD 1 (0.4) 29 (12.3) 141 (70.1) 40 (86.5) 29 (98.4) 4 (100) 0 12.3 87.7
CTX 36 (14.8) 146 (74.6) 52 (95.9) 9 (99.6) 1 (100) 74.6 21.3 4.1
CDN 58 (23.8) 126 (75.4) 51 (96.3) 7 (99.2) 2 (100) NA NA NA
ERY 67 (27.5) 1 (27.9) 3 (29.1) 173 (100) 27.5 0 72.5
CLR 66 (27.0) 1 (27.5) 1 (27.9) 3 (29.1) 1 (29.5) 172 (100) 27.5 0 72.5
LVX 7 (2.9) 99 (43.4) 102 (85.2) 5 (87.3) 1 (87.7) 19 (95.5) 11 (100) 87.3 0.4 12.3
Amoxycillin-susceptible
(MIC £2 mg ⁄L),
penicillin-non-susceptible
(MIC ‡0.12 mg ⁄L)
isolates (n = 81)
PEN 4 (4.9) 3 (8.6) 2 (11.1) 53 (76.5) 19 (100) 0 79 21
AMC 4 (4.9) 1 (6.2) 4 (11.1) 57 (81.5) 15 (100) 100 0 0
CXM 1 (1.2) 1 (2.5) 2 (4.9) 3 (8.6) 6 (16.0) 49 (76.5) 19 (100) 8.6 7.4 84
CFM 1 (1.2) 2 (3.7) 1 (4.9) 6 (12.3) 12 (27.2) 59 (100) NA NA NA
CPD 1 (1.2) 4 (6.2) 4 (11.1) 20 (35.8) 51 (98.8) 1 (100) 11.1 24.7 64.2
CTX 4 (4.9) 4 (9.9) 19 (33.3) 51 (96.3) 3 (100) 96.3 3.7 0
CDN 8 (9.9) 15 (28.4) 56 (97.5) 2 (100) NA NA NA
ERY 44 (54.3) 1 (55.6) 1 (56.8) 2 (59.3) 2 (61.7) 31 (100) 54.3 1.1 44.4
CLR 44 (54.3) 2 (56.8) 1 (58.0) 2 (60.5) 1 (61.7) 31 (100) 54.3 2.5 43.2
LVX 21 (25.9) 50 (87.7) 3 (91.4) 1 (92.6) 2 (95.1) 4 (100) 91.4 1.2 7.4
MIC50 and MIC90 are shown in bold.
NA, no CLSI breakpoints available; PEN, penicillin; AMC, amoxycillin–clavulanic acid (2:1); CXM, cefuroxime; CFM, cefixime; CPD, cefpodoxime, CTX, cefotaxime; CDN,
cefditoren; ERY, erythromycin; CLR, clarithromycin; LVX, levofloxacin; S, susceptible; I, intermediate; R, resistant.
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percentage of susceptible, intermediate and resist-
ant isolates. Rates of resistance to all antimicrobial
agents with defined breakpoints, except cefotax-
ime and levofloxacin, were significantly higher
(p <0.001) among amoxycillin-non-susceptible
isolates. The only antibiotic for which suscepti-
bility rates were similar among amoxycillin-sus-
ceptible and amoxycillin-non-susceptible isolates
was levofloxacin (c. 90%). There was c. 95%
susceptibility to cefotaxime among amoxycillin-
susceptible isolates vs. 75% among non-suscept-
ible isolates. Susceptibility to macrolides was
c. 55% among amoxycillin-susceptible isolates
vs. 25% among non-susceptible isolates; suscep-
tibility to all b-lactams tested, except cefotaxime,
was 0% for amoxycillin-non-susceptible isolates.
On the basis of MIC90 values, cefditoren (1 mg ⁄L)
had the highest intrinsic activity against amoxy-
cillin-non-susceptible isolates, followed by cefo-
taxime (2 mg ⁄L), amoxycillin–clavulanic acid,
cefpodoxime and levofloxacin (8 mg ⁄L), and
cefuroxime axetil, cefixime and macrolides
(‡16 mg ⁄L).
Of 244 amoxycillin-non-susceptible S. pneumo-
niae isolates, 97, 68, 45 and 17 isolates belonged to
serogroup ⁄ serotype 14, 6, 9 and 23, respectively.
The remaining 17 isolates were non-typeable
(eight isolates) or belonged to other serotypes.
Serogroup ⁄ serotypes 14, 23, 9 and 6 were the
most frequent among the 81 amoxycillin-suscept-
ible isolates, being represented by 25, 19, ten and
nine isolates, respectively.
Among the isolates analysed by PFGE, 93%
(174 ⁄ 188) of amoxycillin-non-susceptible and
76% (42 ⁄ 55) of amoxycillin-susceptible isolates
were related to the four multiresistant Spanish
epidemic clones (v2 = 11.29, p <0.01). Isolates of
the Spain14-5 and Spain6B-2 clones were signifi-
cantly more frequent (p <0.001) among amoxycil-
lin-non-susceptible isolates (23% vs. 5.5%, and
40% vs. 11%, respectively), but this was not the
case for the Spain9V-3 clone (25% vs. 36%; p 0.8).
Isolates of the Spain23F-1 clone were present more
often among amoxycillin-susceptible isolates than
among amoxycillin-non-susceptible isolates (5.9%
vs. 24%; p <0.001). More than 90% of the isolates
of the Spain14-5 and Spain6B-2 clones were
amoxycillin-non-susceptible.
Table 2 shows the MIC50 and MIC90 values
and susceptibility rates for isolates belonging to
the four Spanish multidrug-resistant clones. In
total, the isolates showed 0–5% susceptibility to
penicillins, cefuroxime axetil and cefpodoxime.
Rates of susceptibility to cefotaxime and levo-
floxacin were 82–96% for Spain23F-1, Spain6B-2,
and Spain9V-3 isolates. Isolates of clone Spain14-5
were the most problematic in terms of resistance,
with only c. 66% susceptibility to levofloxacin,
c. 57% susceptibility to cefotaxime, and >90%
resistance to all other drugs tested with defined
breakpoints. This clone is thought to have
undergone a number of recombinational events
and ⁄ or point mutations that are responsible for
the development of antibiotic resistance [7,8]. In
terms of MIC90 values, cefditoren exhibited the
highest intrinsic activity (1 mg ⁄L), followed by
cefotaxime and penicillin (2 mg ⁄L), and amoxy-
cillin–clavulanic acid, cefpodoxime and levo-
floxacin (8 mg ⁄L). The reported two-fold higher
intrinsic activity of cefditoren as compared
with cefotaxime against S. pneumoniae isolates
exhibiting non-susceptibility to cephalosporins,
Table 2. MIC50 and MIC90 values and susceptibility rates for clinical isolates and reference strains of the Spanish
multidrug-resistant clones tested
Spain14-5 (n = 82) Spain6B-2 (n = 44) Spain9V-3 (n = 66)a Spain23F-1 (n = 24)
ATCC
700902 MIC50 MIC90 %S
ATCC
700670 MIC50 MIC90 %S
ATCC
700671 MIC50 MIC90 %S
ATCC
700669 MIC50 MIC90 %S
PEN 2 2 2 0 2 2 4 0 2 2 4 0 2 2 2 0
AMC 2 4 8 7.3 0.5 8 8 6.8 1 4 8 30 1 1 8 4.2
CXM 8 8 16 0 2 8 16 0 8 4 8 0 4 8 8 4.2
CFM 16 ‡16 ‡16 NA 16 ‡16 ‡16 NA 16 ‡16 ‡16 NA 16 ‡16 ‡16 NA
CPD 2 2 8 0 1 2 4 4.5 2 2 4 3.3 2 2 2 0
CTX 1 1 2 57.3 1 1 2 81.8 1 1 2 85 0.5 1 1 95.8
CDN 0.5 0.5 1 NA 0.5 0.5 1 NA 0.5 0.5 1 NA 0.5 0.5 0.5 NA
ERY £0.12 ‡16 ‡16 4.9 £0.12 ‡16 ‡16 4.5 £0.12 £0.12 4 81.7 £0.12 £0.12 ‡16 66.7
CLR £0.12 ‡16 ‡16 4.9 £0.12 ‡16 ‡16 4.5 £0.12 £0.12 4 81.7 £0.12 £0.12 ‡16 66.7
LVX 0.5 1 8 65.9 1 0.5 1 95.5 1 1 1 98.4 2 1 1 95.8
aIncludes 37 serotype 9 isolates, 26 serotype 14 isolates, two serotype 19F isolates and one serotype 23F isolate showing a pulsed-field gel electrophoresis pattern with a
homology of >80% with that of the reference strain of the Spain9V-3 clone, suggesting a capsular replacement in some isolates.
NA, no CLSI breakpoints available; PEN, penicillin; AMC, amoxycillin–clavulanic acid (2:1); CXM, cefuroxime; CFM, cefixime; CPD, cefpodoxime, CTX, cefotaxime; CDN,
cefditoren; ERY, erythromycin; CLR, clarithromycin; LVX, levofloxacin; S, susceptible.
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macrolides, ketolides or quinolones [9] was
maintained against isolates of the four Spanish
multiresistant clones.
In conclusion, resistance rates to levofloxacin
and cefotaxime were similar for amoxycillin-
susceptible and non-susceptible isolates, while
resistance rates to other cephalosporins and
macrolides were significantly higher among
amoxycillin-non-susceptible isolates. Isolates
belonging to the Spain14-5 and Spain6B-2 clones
were found most frequently among amoxycillin-
non-susceptible isolates.
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ABSTRACT
Plasmid-mediated quinolone resistance is being
reported increasingly worldwide among isolates
of enterobacteria. This resistance is mostly asso-
ciated with Qnr-like determinants that confer
resistance to quinolones, e.g., nalidixic acid, and
reduced susceptibility to fluoroquinolones. This
study investigated whether amino-acid substitu-
tions in QnrA1 and QnrS1 determinants might be
responsible for an enhancement of resistance to
quinolones and, particularly, to fluoroquinolones.
However, random and site-directed mutagenesis
failed to identify any single amino-acid substitu-
tion that could be responsible for higher levels of
resistance to quinolones or fluoroquinolones,
indicating that the selection of such mutants
in vivo is probably a rare event.
Keywords Escherichia coli, mutation, plasmid-medi-
ated, Qnr, quinolone resistance
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